ArticleInternal and emergency medicine2026
Angiotensin receptor-neprilysin inhibitor versus angiotensin-converting enzyme inhibitor for osteoporosis risk in patients with heart failure.
Article in Internal and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research presents a real-world study investigating the association between angiotensin receptor-neprilysin inhibitor (ARNI) versus angiotensin-converting enzyme inhibitors (ACEI) use and the risk of osteoporosis in patients with heart failure (HF). During the study period from 2017 to 2022, HF patients were classified as users of ACEI or ARNI based on prescription records. After 1:1 propensity score matching, a total of 12,808 HF patients were included, with 6,404 patients in each treatment group (ACEIs vs. ARNIs). The unadjusted model included only treatment exposure, whereas the adjusted model accounted for potential confounders. In the risk factor analysis for osteoporosis among patients with HF, use of ARNI was associated with a significantly lower risk of osteoporosis compared with ACEI in the multivariable-adjusted model (adjusted HR [aHR] 0.6, 95% CI 0.4-0.88, p = 0.0092). Among HF patients, ARNI use was associated with a lower risk of osteoporosis than ACEI use.
Indexed as
Identifiers
42821020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.